Related Experiment Video
Updated: Oct 26, 2025
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy
1Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Background:
Uveal melanoma (UM) is a rare subtype of melanoma that generally has a poor prognosis once it has metastasized. Clinical trials evaluating immune checkpoint inhibitors (ICIs) in UM have demonstrated response rates lower than those seen in cutaneous melanoma. Despite lower efficacy demonstrated in initial ICI studies, there are a number of ongoing clinical trials investigating novel immunotherapy approaches in UM.
Summary:
This review aims to summarize important ongoing clinical trials investigating immunotherapeutic approaches in UM and previous trials that have evaluated a number of immunologic interventions. A thorough clinical trial investigation was conducted through clinicaltrials.gov using the disease search terms "uveal melanoma" and "ocular melanoma," excluding non-immunotherapy-related trials. Here, we report on ICI, vaccine, adoptive T cells, and combination immunotherapy trials in UM.
Key Messages:
There is an increasing effort in the search for new, effective therapies for this difficult-to-treat disease, with immunotherapeutic approaches being of particular interest. Increasing knowledge of UM biology and development of new biomarkers will direct future drug development and trial design.
Insights
Uveal melanoma (UM) research is exploring new immunotherapies. This review summarizes ongoing clinical trials for this rare cancer, focusing on immune checkpoint inhibitors, vaccines, and cell therapies.
Area of Science:
- Oncology
- Immunology
- Clinical Trials
Background:
- Uveal melanoma (UM) is a rare cancer with poor prognosis upon metastasis.
- Current immune checkpoint inhibitor (ICI) efficacy in UM is limited compared to cutaneous melanoma.
- Novel immunotherapies are under investigation for UM treatment.
Purpose of the Study:
- To review ongoing clinical trials for immunotherapeutic approaches in uveal melanoma.
- To summarize previous trials of immunologic interventions for UM.
- To report on ICI, vaccine, adoptive T-cell, and combination immunotherapy trials in UM.
Main Methods:
- Conducted a clinical trial investigation using clinicaltrials.gov.
- Utilized search terms "uveal melanoma" and "ocular melanoma."
- Excluded non-immunotherapy trials from the review.
Main Results:
- Identified and summarized various ongoing immunotherapy trials in UM.
- Detailed findings from ICI, vaccine, adoptive T-cell, and combination immunotherapy studies.
- Highlighted the range of immunologic interventions being explored.
Conclusions:
- Significant efforts are underway to find effective therapies for uveal melanoma.
- Immunotherapeutic approaches are a key focus in UM research.
- Advancements in UM biology and biomarkers will shape future treatment strategies.
More Related Videos
05:46Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
06:46Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
